Seroatlas · Human Serome Atlas

TGFBR3L

Transforming growth factor-beta receptor type 3-like protein

Also known as: GEMP, TGR3L_HUMAN

Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene

Protein identityUniProt · HPA

UniProt accession: H3BV60
Gene: TGFBR3L
Ensembl: ENSG00000260001
Chromosome: 19
Canonical length: 292 aa
Protein class: Predicted membrane proteins
Subcellular location: Vesicles

OverviewNCBI Gene

Predicted to enable glycosaminoglycan binding activity; transforming growth factor beta receptor activity; and type II transforming growth factor beta receptor binding activity. Predicted to contribute to transforming growth factor beta binding activity. Predicted to be involved in several processes, including epithelial to mesenchymal transition; regulation of transforming growth factor beta receptor signaling pathway; and transforming growth factor beta receptor signaling pathway. Predicted to be located in plasma membrane. [provided by Alliance of Genome Resources, Jul 2025]

Canonical amino-acid sequenceUniProt

292 residues, UniProt reviewed canonical sequence.

>H3BV60|TGFBR3L
     1  MLGTVLLLAL LPGITTLPSG PPAPPFPAAP GPWLRRPLFS LKLSDTEDVF PRRAGPLEVP
    61  ADSRVFVQAA LARPSPRWGL ALHRCSVTPS SRPAPGPALA LLREGCPADT SVAFPPPPPP
   121  SPGAARPARF SFRLRPVFNA SVQFLHCQLS RCRRLRGVRR APAPLTPPPP PPPSRCLPQD
   181  EACADTGSGS AEGLAADGPH LHTLTQPIVV TVPRPPPRPP KSVPGRAVRP EPPAPAPAAL
   241  EPAPVVALVL AAFVLGAALA AGLGLVCAHS APHAPGPPAR ASPSGPQPRR SQ

LocalizationUniProt · AlphaFold · HPA

Whether an antibody against TGFBR3L can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.

Antibody reachability: Cell surface
Secreted: No
Transmembrane segments: 1
Mean surface accessibility (rSASA): 0.5
Highest tissue expression: 33 nTPM

Expression across tissuesHPA

Tissue

pituitary gland: 33 nTPM
liver: 3.4 nTPM
duodenum: 1.9 nTPM
small intestine: 1.5 nTPM
cerebellum: 1.4 nTPM
endometrium: 1.4 nTPM

Single-cell type

gonadotrophs: 949 nCPM
pancreatic islet cells: 24 nCPM
somatotrophs: 19 nCPM
late spermatids: 18 nCPM
pituitary stem cells: 17 nCPM
smooth muscle cells: 16 nCPM

Immune cell

basophil: 0.5 nTPM
neutrophil: 0.5 nTPM
gdT-cell: 0.3 nTPM
memory CD8 T-cell: 0.3 nTPM
naive CD8 T-cell: 0.3 nTPM
eosinophil: 0.2 nTPM

Brain region

cerebellum: 7.5 nTPM
cerebral cortex: 6.9 nTPM
white matter: 5.4 nTPM
basal ganglia: 5.1 nTPM
hypothalamus: 5 nTPM
pons: 5 nTPM

Genetic constraint and essentialitygnomAD · DepMap

Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.

gnomAD LOEUF (loss-of-function intolerance): 1.38
gnomAD pLI: 0.08
gnomAD missense Z: 0.67
DepMap mean gene effect: -0.07
DepMap dependency class: selective

OntologyGO

Biological processes

Molecular functions

Cellular components

plasma membrane

Protein domainsUniProt · Pfam · InterPro

KeywordsUniProt

InteractionsUniProt · HPA

Protein binding partners of TGFBR3L in the human serome: UniProt-annotated complex subunits plus reported interactors. Each links to its own Seroatlas record.

INHA

Antibody and autoantibody relevanceSeroatlas analysis

Seroatlas reads TGFBR3L as an antibody target. Whether an autoantibody or antibody against TGFBR3L could matter depends on whether native TGFBR3L is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.

TGFBR3L is annotated at the cell surface, where native TGFBR3L is exposed to circulating antibodies and is a prime autoantibody target that could block, deplete, or overstimulate it.

Annotation status

The present source text does not explicitly label TGFBR3L as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.

Loading the interactive Seroatlas protein explorer...